Investment Considerations HyBryte™ is advancing through an actively enrolling confirmatory Phase 3 trial with interim analysis expected in 2Q 2026 and top-line results anticipated in the second half of 2026. SGX945 has demonstrated biological efficacy in a published Phase 2 study and has received a positive orphan designation opinion from the EMA in addition to … Continue reading “Soligenix Inc. (NASDAQ: SNGX)”
| Symbol | Release | Time |
|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |